A Phase 1 interventional study of Tirzepatide and Prefilled syringe (PFS) in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-18.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare the amount of tirzepatide that gets into the blood stream and how long it takes the body to get rid of it, when given as a solution formulation via an autoinjector versus a conventional prefilled syringe. The tolerability of tirzepatide will also be evaluated and information about any adverse effects experienced will be collected.
Screening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be about 14 weeks, including screening.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received single dose of 5 milligram (mg) Tirzepatide by subcutaneous injection (SC) via an autoinjector (AI) in one of two study periods.
Drug: Tirzepatide · Device: Auto-injector (AI)
Participants received single dose of 5mg Tirzepatide by subcutaneous injection (SC) via a prefilled syringe (PFS) in one of two study periods.
Drug: Tirzepatide · Device: Prefilled syringe (PFS)
Administered SC
Also known as: LY3298176
PFS used to administer tirzepatide
AI used to administer tirzepatide
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Infinity (AUC0toinf)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide from Time Zero to Infinity (AUC0toinf) was reported.
Time frame: Predose, 8hours(h), 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h, 336h , 480h, 864h postdose
PK: Maximum Observed Plasma Concentration (Cmax) of Tirzepatide
PK: Maximum Observed Plasma Concentration (Cmax) of Tirzepatide was reported
Time frame: Predose, 8hours(h), 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h, 336h , 480h, 864h postdose
| Milestone | Sequence A | Sequence B |
|---|---|---|
| Started | 24 | 23 |
| Received at least one dose of study drug | 22 | 23 |
| Completed | 21 | 20 |
| Not completed | 3 | 3 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Adverse event | 1 | 2 |
| Milestone | Sequence A | Sequence B |
|---|---|---|
| Started | 21 | 20 |
| Received at least one dose of study drug | 21 | 20 |
| Completed | 21 | 20 |
| Not completed | 0 | 0 |
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide from Time Zero to Infinity (AUC0toinf) was reported.
| Nanogram*hour per milliliter (ng*h/mL) | 5 mg Tirzepatide AI | 5 mg Tirzepatide PFS |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Infinity (AUC0toinf) | 101000 ± 18 | 104000 ± 18 |
PK: Maximum Observed Plasma Concentration (Cmax) of Tirzepatide was reported
| Nanogram per Milliliter (ng/mL) | 5 mg Tirzepatide AI | 5 mg Tirzepatide PFS |
|---|---|---|
| PK: Maximum Observed Plasma Concentration (Cmax) of Tirzepatide | 530 ± 25 | 556 ± 22 |
Collected over Up to 72 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 5 mg Tirzepatide AI | 0/42 (0%) | 0/42 (0%) | 40/42 (95.2%) |
| 5 mg Tirzepatide PFS | 0/44 (0%) | 1/44 (2.3%) | 42/44 (95.5%) |
| Event | 5 mg Tirzepatide AI | 5 mg Tirzepatide PFS |
|---|---|---|
| Catheter site phlebitisGeneral disorders | 0/42 | 1/44 |
| Event | 5 mg Tirzepatide AI | 5 mg Tirzepatide PFS |
|---|---|---|
| Abdominal distensionGastrointestinal disorders | 20/42 | 29/44 |
| Decreased appetiteMetabolism and nutrition disorders | 24/42 | 22/44 |
| VomitingGastrointestinal disorders | 14/42 | 16/44 |
| NauseaGastrointestinal disorders | 14/42 | 12/44 |
| HeadacheNervous system disorders | 8/42 | 11/44 |
| EructationGastrointestinal disorders | 5/42 | 8/44 |
| Vessel puncture site bruiseGeneral disorders | 7/42 | 2/44 |
| Catheter site bruiseGeneral disorders | 3/42 | 6/44 |
| Catheter site erythemaGeneral disorders | 4/42 | 6/44 |
| DiarrhoeaGastrointestinal disorders | 4/42 | 2/44 |
All randomized participants.
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 44.6 ± 11.8 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 10 |
| Male | 37 |
| Ethnicity (NIH/OMB)(Participants) | All Participants |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 47 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 47 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | All Participants |
|---|---|
| Singapore | 47 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2019 to primary completion in Dec 2019, 3 months.
Results were first posted in Apr 2023, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide